{
    "nct_id": "NCT00675623",
    "title": "A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION)",
    "status": "COMPLETED",
    "last_update_time": "2016-09-24",
    "description_brief": "The Connection Study is a six-month confirmatory Phase 3 study to determine the safety and efficacy of Dimebon in the treatment of mild-to-moderate Alzheimer's disease (AD).",
    "description_detailed": "This study is a randomized, placebo-controlled 6-month study designed as an adequate and well-controlled trial to demonstrate the safety and efficacy of Dimebon in the treatment of patients with mild-to-moderate AD. Dimebon is an investigational drug for Alzheimer's disease. The target of Dimebon's mechanism of action are the mitochondria (a cell's primary source of energy).The Connection Study is the second of two pivotal studies evaluating the effect of Dimebon. It is a 6-month study enrolling 525 patients in the United States, Europe, and South America. All patients completing the 6-month study will be eligible to receive Dimebon in an open-label extension trial.\n\nThe patient population will be carefully selected to ensure inclusion of patients with AD, rather than other types of dementia. Mild-to-moderate disease will be defined by the screening Mini-Mental State Examination (MMSE). Patients will attend study visits with caregivers who will provide information about the patient's condition.",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "Dimebon (latrepirdine)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The CONNECTION trial is a global Phase 3, randomized, double\u2011blind, placebo\u2011controlled study of oral Dimebon (latrepirdine) in mild\u2011to\u2011moderate Alzheimer\u2019s disease with co\u2011primary endpoints assessing cognition (ADAS\u2011Cog) and global function (CIBIC\u2011plus), indicating the trial aimed to improve cognitive/global function rather than test a biologic (e.g., antibody) intervention. \ue200cite\ue202turn0search0\ue202turn0search5\ue201",
        "Act: Drug identity and type \u2014 Dimebon is the small\u2011molecule latrepirdine (originally a nonselective antihistamine from Russia) repurposed for AD; it is not a biologic (monoclonal antibody or vaccine). Clinical programs (including CONNECTION) tested oral latrepirdine vs placebo. \ue200cite\ue202turn1search1\ue202turn0search5\ue201",
        "Act (mechanism): Latrepirdine\u2019s mechanism is heterogeneous and incompletely understood \u2014 reported actions include multireceptor modulation (antihistamine activity), effects on mitochondrial function, modulation of autophagy, and influence on neurotransmission/ion channels \u2014 but it was not developed as a specific amyloid\u2011 or tau\u2011targeting drug. These mechanistic data support that it was pursued as a neuroprotective/cognitive\u2011enhancing small molecule rather than a disease\u2011targeted anti\u2011amyloid/tau biologic. \ue200cite\ue202turn1search2\ue202turn1search5\ue202turn1search3\ue201",
        "Reflect: Clinical outcomes \u2014 the CONNECTION Phase 3 failed to meet co\u2011primary endpoints (no cognitive/global benefit vs placebo) and subsequent reviews/meta\u2011analyses concluded little or no effect on cognition though a modest behavioral benefit was suggested; this aligns with classifying the intervention as a cognitive/neuroprotective small\u2011molecule candidate rather than a disease\u2011targeted biologic. \ue200cite\ue202turn0search0\ue202turn1search4\ue201",
        "Conclusion / classification rationale: Under the provided category definitions, Dimebon (latrepirdine) best fits 'cognitive enhancer' \u2014 a small\u2011molecule intended to improve cognition/neuroprotection without a clear, specific anti\u2011amyloid or anti\u2011tau disease\u2011target. Note: it is a small molecule (not a biologic), but because its development was not based on a defined Alzheimer\u2019s pathology target, it is classified as a cognitive enhancer rather than a 'disease\u2011targeted small molecule.' Key sources: Pfizer/Medivation CONNECTION results, reviews summarizing latrepirdine\u2019s repurposing and uncertain multi\u2011target mechanisms, and Cochrane/meta\u2011analytic assessments. \ue200cite\ue202turn0search0\ue202turn1search1\ue202turn1search4\ue201"
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: The CONNECTION Phase 3 trial tested oral Dimebon (latrepirdine) as a small\u2011molecule cognitive enhancer/neuroprotective candidate to improve cognition and global function in mild\u2011to\u2011moderate AD, not as a targeted anti\u2011amyloid or anti\u2011tau biologic. Evidence shows latrepirdine is a repurposed nonselective antihistamine/small molecule with heterogeneous proposed actions (multi\u2011receptor modulation, mitochondrial effects, stimulation of autophagy and potential neuroprotection) consistent with a synaptic\u2011plasticity / neuroprotection classification rather than a specific pathology\u2011directed CADRO category. \ue200cite\ue202turn0search0\ue202turn1search7\ue201",
        "Act: Extracted trial/drug details \u2014 Trial: CONNECTION (Phase 3, DBPC, mild\u2011to\u2011moderate AD) testing Dimebon (latrepirdine). Drug identity: small\u2011molecule latrepirdine (originally an antihistamine). Mechanistic summary from the literature: multi\u2011receptor activity (histamine, serotonin, dopamine receptors), reported mitochondrial and autophagy effects and proposed neuroprotective/cognitive\u2011enhancing actions. The program did not pursue a defined amyloid/tau immunotherapy or single molecular pathology target in Phase 3. Based on these facts, the best CADRO fit is M) Synaptic Plasticity/Neuroprotection. \ue200cite\ue202turn0search0\ue202turn1search7\ue202turn1search3\ue201",
        "Reflect: The classification aligns with CADRO because latrepirdine was developed and tested as a cognitive enhancer/neuroprotective small molecule with multiple, incompletely understood actions (including autophagy/mitochondrial modulation) rather than as a targeted anti\u2011amyloid or anti\u2011tau therapy. Although latrepirdine has been reported to influence autophagy and APP/A\u03b2 metabolism in preclinical studies (which could also implicate proteostasis pathways), its clinical development and stated intent (improve cognition/global function) support the Synaptic Plasticity/Neuroprotection category rather than a primary Proteostasis (I) or Metabolism (J) assignment. If one emphasized preclinical autophagy effects over the clinical intent, a secondary argument for I) Proteostasis could be made, but the clearest, most specific CADRO mapping is M. \ue200cite\ue202turn1search6\ue202turn1search5\ue201",
        "Web search results (key sources used to support the classification):",
        "- Pfizer/Medivation press release reporting CONNECTION top\u2011line Phase 3 results (CONNECTION did not meet co\u2011primary endpoints; dimebon was well tolerated). \ue200cite\ue202turn0search0\ue201",
        "- Pfizer/Medivation announcement of CONCERT (Phase 3) negative results and program discontinuation. \ue200cite\ue202turn0search3\ue201",
        "- Review article (open access) summarizing latrepirdine pharmacology: multi\u2011receptor binding (H1, 5\u2011HT6, dopamine, adrenergic, etc.), and heterogeneous actions relevant to cognition/neuroprotection. \ue200cite\ue202turn1search7\ue201",
        "- Molecular Psychiatry / Mount Sinai work showing latrepirdine stimulates autophagy and reduces \u03b1\u2011synuclein accumulation in cells and mouse brain (preclinical evidence for autophagy/proteostasis effects). \ue200cite\ue202turn1search3\ue202turn1search4\ue201",
        "- Journal of Alzheimer\u2019s Disease / related studies reporting latrepirdine enhances autophagy and reduces intracellular A\u03b242 in yeast/cellular models (preclinical proteostasis data). \ue200cite\ue202turn1search1\ue202turn1search5\ue201"
    ]
}